GENB earnings date and last-quarter result: next report 2026-08-06, P/E -2.79. Updated 2026-07-23.
Generate Biomedicines (GENB) Research Hub
Generate Biomedicines (GENB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 12.35 USD (-0.48%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.79, market cap 1.79B. This hub links to the full technical, earnings and options research available for GENB.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.35 USD (-0.48%) |
| 52-week range | 11.94 USD – 22.67 USD |
| Trend regime | Range |
| 14-day RSI | 39.1 (Bearish) |
| Trailing P/E | -2.79 |
| Market cap | 1.79B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for GENB
Covered Call on GENB: how it works, illustrative setup around the real 12.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GENB: how it works, illustrative setup around the real 12.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GENB: how it works, illustrative setup around the real 12.35 USD price, max profit/loss, breakeven and when to use it. Educational.
GENB technical analysis: range, last 12.35 USD, RSI 39.1, 52w range 11.94 USD–22.67 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GENB in?
Generate Biomedicines (GENB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GENB in an uptrend or downtrend?
As of 2026-10-26, GENB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GENB's trailing P/E ratio?
GENB's trailing P/E is -2.79, with a market cap of 1.79B. See the earnings research page for full valuation detail.
When does GENB next report earnings?
GENB is next scheduled to report earnings on 2026-08-06.